| Name | Cvs Pharmacy #00026 |
|---|---|
| Organization Name | Cvs Pharmacy Inc |
| Location | 590 Fellsway, Medford, Massachusetts 02155 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Phone | (781) 391-2668 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
A Ludwig Cancer Research study has identified and preclinically validated combination treatments for the brain metastases of breast cancer, a common and typically lethal manifestation of the malignancy.
The human body is controlled by electrical impulses in, for example, the brain, the heart and nervous system.
"After three decades of global emergency responses and a series of scientific breakthroughs in the fight against HIV/AIDS, it is now tempting to ask if we are marching towards the end of AIDS," an editorial in the Lancet states.
To address the gaps in the knowledge, a team of researchers from the University of California and the Gladstone Institute of Virology conducted 39-parameter phenotyping by cytometry by time of flight (CyTOF) on 33 longitudinal specimens from 11 mRNA-vaccinated individuals, of which six had previously been infected and recovered from COVID-19.
The U.S. Food and Drug Administration today expanded the approved use of Imbruvica (ibrutinib) to treat patients with chronic lymphocytic leukemia (CLL) who carry a deletion in chromosome 17 (17p deletion), which is associated with poor responses to standard treatment for CLL. Imbruvica received a breakthrough therapy designation for this use.
› Verified 6 days ago
| NPI Number | 1598864944 |
| Organization Name | CVS PHARMACY INC |
| Doing Business As | CVS PHARMACY #00026 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Address | 590 Fellsway, Medford, MA 02155 |
| Phone Number | 781-391-2668 |
News Archive
A Ludwig Cancer Research study has identified and preclinically validated combination treatments for the brain metastases of breast cancer, a common and typically lethal manifestation of the malignancy.
The human body is controlled by electrical impulses in, for example, the brain, the heart and nervous system.
"After three decades of global emergency responses and a series of scientific breakthroughs in the fight against HIV/AIDS, it is now tempting to ask if we are marching towards the end of AIDS," an editorial in the Lancet states.
To address the gaps in the knowledge, a team of researchers from the University of California and the Gladstone Institute of Virology conducted 39-parameter phenotyping by cytometry by time of flight (CyTOF) on 33 longitudinal specimens from 11 mRNA-vaccinated individuals, of which six had previously been infected and recovered from COVID-19.
The U.S. Food and Drug Administration today expanded the approved use of Imbruvica (ibrutinib) to treat patients with chronic lymphocytic leukemia (CLL) who carry a deletion in chromosome 17 (17p deletion), which is associated with poor responses to standard treatment for CLL. Imbruvica received a breakthrough therapy designation for this use.
› Verified 6 days ago
News Archive
A Ludwig Cancer Research study has identified and preclinically validated combination treatments for the brain metastases of breast cancer, a common and typically lethal manifestation of the malignancy.
The human body is controlled by electrical impulses in, for example, the brain, the heart and nervous system.
"After three decades of global emergency responses and a series of scientific breakthroughs in the fight against HIV/AIDS, it is now tempting to ask if we are marching towards the end of AIDS," an editorial in the Lancet states.
To address the gaps in the knowledge, a team of researchers from the University of California and the Gladstone Institute of Virology conducted 39-parameter phenotyping by cytometry by time of flight (CyTOF) on 33 longitudinal specimens from 11 mRNA-vaccinated individuals, of which six had previously been infected and recovered from COVID-19.
The U.S. Food and Drug Administration today expanded the approved use of Imbruvica (ibrutinib) to treat patients with chronic lymphocytic leukemia (CLL) who carry a deletion in chromosome 17 (17p deletion), which is associated with poor responses to standard treatment for CLL. Imbruvica received a breakthrough therapy designation for this use.
› Verified 6 days ago
Cvs Pharmacy #01010 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 85 High St, Medford, Massachusetts 02155 Phone: (781) 396-4770 | |
Cvs Pharmacy#17736 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 471 Salem Street, Medford, Massachusetts 02155 Phone: (781) 396-1001 | |
Cvs Pharmacy #00026 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 590 Fellsway, Medford, Massachusetts 02155 Phone: (781) 391-2668 | |
Cvs Pharmacy #00252 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 55 Riverside Ave, Medford, Massachusetts 02155 Phone: (781) 395-1515 | |
Walgreens#19536 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 467 Salem Street, Medford, Massachusetts 02155 Phone: (781) 396-8350 |